Hitachi High-Tech Corporation has entered into a strategic partnership (the Partnership) with Invivoscribe, Inc., a global provider of blood cancer testing kits and services, by undertaking a minority investment-based, third-party allotment of shares. The Partnership aims to accelerate the molecular diagnostics and precision medicine businesses of both companies by combining Invivoscribe's technology, assay and bioinformatics development, global clinical testing, and international regulatory expertise with Hitachi High-Tech's core expertise in measurement and analysis systems technologies. Invivoscribe is a privately-held, California-based life science corporation with seven wholly-owned subsidiaries in five countries, including clinical laboratories in four countries.

Invivoscribe is engaged in three core business functions: 1) testing services for blood cancers, 2) global sales and distribution of test kits and licensing bioinformatics software, and 3) the development and commercialization of companion diagnostics to support pharmaceutical approval of new oncology treatments. Hitachi High-Tech's Analytical & Medical Solutions Business aims to support emerging businesses in the life science and healthcare industries while building out its own in vitro diagnostics (IVD) business. This Partnership is part of Hitachi High Tech's growth strategy of strengthening this molecular diagnostics business, whose mission is to contribute to the early detection and treatment of cancer, and discover new drugs, by providing molecular cancer diagnostics to all people, thereby realizing a healthy and secure society.

Through this strategic partnership, Hitachi High-Tech aims to cooperate across development, manufacturing, sales and testing services, while developing systems that provide solutions that better address the on-site needs of cancer diagnosis and monitoring throughout the course of treatment.